logo

SGRL vs SUDEEPPHRM: Stock Comparison

SHREE GANESH REMEDIES vs SUDEEP PHARMAUpdated 19 Oct 26, 4:08 PM ISTNSE & company filings

SUDEEP PHARMA is the larger company by market capitalisation. SHREE GANESH REMEDIES shows a lower P/E, while SUDEEP PHARMA shows a higher dividend yield and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

SGRL leads 2; SUDEEPPHRM leads 3 of 9

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

SGRLSUDEEPPHRM

Valuation lens

What price are you paying?

Market CapContext only
₹887 Cr
₹11,289 Cr
P/E RatioSGRL has the lower reading
57.49x ✓
61.74x
P/B RatioSGRL has the lower reading
5.44x ✓
12.78x
EPSSUDEEPPHRM has the higher reading
₹0.87
₹3.59 ✓
Book ValueContext only
₹126.95
₹79.51
Dividend YieldSUDEEPPHRM has the higher reading
0%
0.15% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
SUDEEPPHRM is the larger company
₹11,289 Cr vs ₹887 Cr
P/E Ratio
SGRL has a lower P/E
57.49x vs 61.74x
P/B Ratio
SGRL has a lower P/B
5.44x vs 12.78x
EPS
SUDEEPPHRM has higher earnings per share
₹3.59 vs ₹0.87
Dividend Yield
SUDEEPPHRM has a higher dividend yield
0.15% vs 0%
Net Margin
SUDEEPPHRM has a higher net margin
27.14% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Price

MetricSGRLSUDEEPPHRM
Live Price₹690.1₹1,003.3
Day Change-0.32%0.26%
Volume2,9121.95 L
52-Week High₹749.85₹1,378
52-Week Low₹477.05₹524.05
Distance from 52W High-7.97%-27.19%

Valuation

MetricSGRLSUDEEPPHRM
Market Cap₹887 Cr₹11,289 Cr
P/E Ratio57.49x61.74x
P/B Ratio5.44x12.78x
EPS₹0.87₹3.59
Book Value₹126.95₹79.51
Dividend Yield0%0.15%

Growth

MetricSGRLSUDEEPPHRM
Revenue Growth (TTM YoY)0%0%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricSGRLSUDEEPPHRM
ROE—19.41%
ROCE—17.66%
Net Margin0%27.14%
Operating Margin—36.7%
Debt to Equity—0.17x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricSGRLSUDEEPPHRM
Promoter Holding72.84%76.15%
FII Holding0%2.93%▲ 1.12 pp
DII Holding0.52%▲ 0.52 pp14.05%▼ 1.6 pp
Public Holding26.64%▼ 0.52 pp6.87%▲ 0.48 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SHREE GANESH REMEDIES and SUDEEP PHARMA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.